Browsing: anaesthesia

In a recent announcement, the Food and Drug Administration (FDA) has urged healthcare professionals to promptly report any adverse reactions linked to the use of anaesthesia. This directive comes in response to mounting concerns raised by healthcare practitioners regarding the efficacy of certain anaesthesia products. Particularly, those containing bupivacaine, a potent local anaesthetic, have drawn significant attention. The FDA’s stance aims to address these concerns and ensure patient safety in anaesthesia administration.

Sheikh Shakhbout Medical City (SSMC) in Abu Dhabi, one of the UAE’s key hospitals, has ceased the use of Desflurane, a widely employed anaesthetic but also a major contributor to greenhouse gas emissions. This bold move aligns with the Department of Health – Abu Dhabi’s healthcare sustainability goals and represents a significant stride in the healthcare sector’s contribution towards environmental conservation. Desflurane, commonly used during surgeries to induce anaesthesia, has been identified as an environmental culprit. It contributes substantially to greenhouse gases, trapping heat and aggravating global warming.